Vacuolar (H+)-ATPase Critically Regulates Specialized Proresolving Mediator Pathways in Human M2-like Monocyte-Derived Macrophages and Has a Crucial Role in Resolution of Inflammation

Key Points V-ATPase is required for ERK-mediated 15-LOX-1 expression during M2 polarization. Inhibition of V-ATPase prevents 15-LOX-1–mediated SPM biosynthesis in M2 macrophages. Targeting V-ATPase delays resolution in murine peritonitis with decreased SPM levels. Alternative (M2)-polarized macrophages possess high capacities to produce specialized proresolving mediators (SPM; i.e., resolvins, protectins, and maresins) that play key roles in resolution of inflammation and tissue regeneration. Vacuolar (H+)-ATPase (V-ATPase) is fundamental in inflammatory cytokine trafficking and secretion and was implicated in macrophage polarization toward the M2 phenotype, but its role in SPM production and lipid mediator biosynthesis in general is elusive. In this study, we show that V-ATPase activity is required for the induction of SPM-biosynthetic pathways in human M2-like monocyte-derived macrophages (MDM) and consequently for resolution of inflammation. Blockade of V-ATPase by archazolid during IL-4–induced human M2 polarization abrogated 15-lipoxygenase-1 expression and prevented the related biosynthesis of SPM in response to pathogenic Escherichia coli, assessed by targeted liquid chromatography–tandem mass spectrometry–based metabololipidomics. In classically activated proinflammatory M1-like MDM, however, the biosynthetic machinery for lipid mediator formation was independent of V-ATPase activity. Targeting V-ATPase in M2 influenced neither IL-4–triggered JAK/STAT6 nor the mTOR complex 1 signaling but strongly suppressed the ERK-1/2 pathway. Accordingly, the ERK-1/2 pathway contributes to 15-lipoxygenase-1 expression and SPM formation in M2-like MDM. Targeting V-ATPase in vivo delayed resolution of zymosan-induced murine peritonitis accompanied by decreased SPM levels without affecting proinflammatory leukotrienes or PGs. Together, our data propose that V-ATPase regulates 15-lipoxygenase-1 expression and consequent SPM biosynthesis involving ERK-1/2 during M2 polarization, implying a crucial role for V-ATPase in the resolution of inflammation.

[1]  C. Serhan,et al.  Aging Delays Resolution of Acute Inflammation in Mice: Reprogramming the Host Response with Novel Nano-Proresolving Medicines , 2014, The Journal of Immunology.

[2]  Wolfgang Albrecht,et al.  Skepinone-L is a selective p38 mitogen-activated protein kinase inhibitor. , 2012, Nature chemical biology.

[3]  R. Murphy,et al.  Dual 12/15- and 5-Lipoxygenase Deficiency in Macrophages Alters Arachidonic Acid Metabolism and Attenuates Peritonitis and Atherosclerosis in ApoE Knock-out Mice* , 2009, The Journal of Biological Chemistry.

[4]  R. Sundler,et al.  Bafilomycin A1 inhibits lysosomal, phagosomal, and plasma membrane H+‐ATPase and induces lysosomal enzyme secretion in macrophages , 1995, Journal of cellular physiology.

[5]  J. O’Shea,et al.  Prevention of Organ Allograft Rejection by a Specific Janus Kinase 3 Inhibitor , 2003, Science.

[6]  M. Simons,et al.  Vacuolar ATPase is required for ERK‐dependent wound healing in the Drosophila embryo , 2018, Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society.

[7]  E. Jaffe,et al.  IL-4 protein expression and basal activation of Erk in vivo in follicular lymphoma. , 2008, Blood.

[8]  F. Hobbs,et al.  Identification of a Novel Inhibitor of Mitogen-activated Protein Kinase Kinase* , 1998, The Journal of Biological Chemistry.

[9]  M. Forgac,et al.  Recent Insights into the Structure, Regulation, and Function of the V-ATPases. , 2015, Trends in biochemical sciences.

[10]  C. Serhan,et al.  Pro-Resolving Mediators in Regulating and Conferring Macrophage Function , 2017, Front. Immunol..

[11]  O. Werz,et al.  5-Lipoxygenase, a key enzyme for leukotriene biosynthesis in health and disease. , 2015, Biochimica et biophysica acta.

[12]  G. Feldman,et al.  Monocyte 15-Lipoxygenase Expression Is Regulated by a Novel Cytosolic Signaling Complex with Protein Kinase C δ and Tyrosine-Phosphorylated Stat31 , 2006, The Journal of Immunology.

[13]  M. Landthaler,et al.  Luminescent Dual Sensors Reveal Extracellular pH-Gradients and Hypoxia on Chronic Wounds That Disrupt Epidermal Repair , 2014, Theranostics.

[14]  M. Zaiss,et al.  The double-edged role of 12/15-lipoxygenase during inflammation and immunity. , 2017, Biochimica et biophysica acta. Molecular and cell biology of lipids.

[15]  A. Gilman‐Sachs,et al.  Tumor-Associated a2 Vacuolar ATPase Acts As a Key Mediator of Cancer-Related Inflammation by Inducing Pro-Tumorigenic Properties in Monocytes , 2011, The Journal of Immunology.

[16]  Dudley Lamming,et al.  Akt-mTORC1 signaling regulates Acly to integrate metabolic input to control of macrophage activation , 2016, eLife.

[17]  D. Ito,et al.  Polarization of M2 macrophages requires Lamtor1 that integrates cytokine and amino-acid signals , 2016, Nature Communications.

[18]  P. Isakson,et al.  In vivo characterization of zymosan-induced mouse peritoneal inflammation. , 1994, The Journal of pharmacology and experimental therapeutics.

[19]  D. Gilroy,et al.  CYP450-derived oxylipins mediate inflammatory resolution , 2016, Proceedings of the National Academy of Sciences.

[20]  Y. Dou,et al.  Epigenetic regulation of the alternatively activated macrophage phenotype. , 2009, Blood.

[21]  P. Murray Macrophage Polarization. , 2017, Annual review of physiology.

[22]  J. Benveniste,et al.  Formation of prostaglandins, leukotrienes and paf-acether by macrophages. , 1985, Comparative immunology, microbiology and infectious diseases.

[23]  C. Serhan,et al.  Resolution phase lipid mediators of inflammation: agonists of resolution. , 2013, Current opinion in pharmacology.

[24]  O. Werz,et al.  Selective upregulation of TNF&agr; expression in classically‐activated human monocyte‐derived macrophages (M1) through pharmacological interference with V‐ATPase , 2017, Biochemical pharmacology.

[25]  S. Kundu,et al.  IL-4 and IL-13 employ discrete signaling pathways for target gene expression in alternatively activated monocytes/macrophages. , 2013, Free radical biology & medicine.

[26]  S. Goerdt,et al.  Macrophage activation and polarization: nomenclature and experimental guidelines. , 2014, Immunity.

[27]  H. Claésson,et al.  Mice lacking 12/15-lipoxygenase have attenuated airway allergic inflammation and remodeling. , 2008, American journal of respiratory cell and molecular biology.

[28]  Charles N. Serhan,et al.  Pro-resolving lipid mediators are leads for resolution physiology , 2014, Nature.

[29]  Ji-Yun Kim,et al.  Activation of PI3K, Akt, and ERK during early rotavirus infection leads to V-ATPase-dependent endosomal acidification required for uncoating , 2018, PLoS pathogens.

[30]  D. Gilroy,et al.  Macrophage development and polarization in chronic inflammation. , 2015, Seminars in immunology.

[31]  S. Grinstein,et al.  Contrasting phagosome pH regulation and maturation in human M1 and M2 macrophages , 2014, Molecular biology of the cell.

[32]  William B. Smith,et al.  Selective inhibition of BET bromodomains , 2010, Nature.

[33]  O. Werz,et al.  ERK-mediated regulation of leukotriene biosynthesis by androgens: A molecular basis for gender differences in inflammation and asthma , 2008, Proceedings of the National Academy of Sciences.

[34]  Bjarni V. Halldórsson,et al.  A loss-of-function variant in ALOX15 protects against nasal polyps and chronic rhinosinusitis , 2019, Nature Genetics.

[35]  C. Serhan,et al.  Novel proresolving and tissue‐regenerative resolvin and protectin sulfido‐conjugated pathways , 2015, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[36]  Charles N. Serhan,et al.  Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators , 2008, Nature Reviews Immunology.

[37]  A. Haque,et al.  Bactericidal Activity of Alveolar Macrophages is Suppressed by V-ATPase Inhibition , 2014, Lung.

[38]  C. Serhan,et al.  Identification and Profiling of Specialized Pro-Resolving Mediators in Human Tears by Lipid Mediator Metabolomics. , 2017, Prostaglandins, leukotrienes, and essential fatty acids.

[39]  C. Serhan,et al.  Specific lipid mediator signatures of human phagocytes: microparticles stimulate macrophage efferocytosis and pro-resolving mediators. , 2012, Blood.

[40]  D. Conrad,et al.  Regulation of human 12/15-lipoxygenase by Stat6-dependent transcription. , 2000, American journal of respiratory cell and molecular biology.

[41]  S. Grinstein,et al.  V-ATPases in phagocytic cells. , 1992, The Journal of experimental biology.

[42]  H. Reichenbach,et al.  Archazolids, new cytotoxic macrolactones from Archangium gephyra (Myxobacteria). Production, isolation, physico-chemical and biological properties. , 2003, The Journal of antibiotics.

[43]  A. Vollmar,et al.  Anti-leukemic effects of the V-ATPase inhibitor Archazolid A , 2015, Oncotarget.

[44]  G. Feldman,et al.  Monocyte 15-Lipoxygenase Gene Expression Requires ERK1/2 MAPK Activity , 2010, The Journal of Immunology.

[45]  C. Serhan,et al.  Macrophage Proresolving Mediators-the When and Where. , 2016, Microbiology spectrum.

[46]  O. Werz,et al.  Human macrophages differentially produce specific resolvin or leukotriene signals that depend on bacterial pathogenicity , 2018, Nature Communications.

[47]  D. Sabatini,et al.  An ATP-competitive Mammalian Target of Rapamycin Inhibitor Reveals Rapamycin-resistant Functions of mTORC1* , 2009, Journal of Biological Chemistry.

[48]  G. Evan,et al.  Role of c-MYC in alternative activation of human macrophages and tumor-associated macrophage biology. , 2012, Blood.